GI Cancer
Advertisement
Both of the double-blind, multicenter trials evaluated the major efficacy outcomes of PFS and OS.
The GAP system was found to predict actionable genetic alterations including FGFR2 and IDH.
Campylobacter bacteria have been found to be enriched in primary CRC lesions of patients with metastasis.
The phase 3 KEYNOTE-177 study compared the efficacy of pembrolizumab with chemotherapy for the treatment of MSI-H/dMMR mCRC.
The survival rate benefit increased over time for patients treated with TTFields, with a 13% improvement in OS at 12 months.
A blood-based, non-invasive classifier can serve as an optional tool for conventional methods in the detection of NETs.
Kaplan-Meier curves showed that patients with high TBS had significantly decreased OS and increased recurrence rates.
HERIZON-BTC-01 marks the largest phase IIb clinical trial to date for patients with previously treated HER2-positive disease.
A recent analysis reviewed patient-level data to identify the relationship between pathological response and relapse.
Dr. Kimmie Ng shares the experiences that drive her dedication to seeking improved patient outcomes in GI oncology care.
A recent study compared first-line chemotherapy, as the standard of care for PDAC, with other treatment options.
A recent systematic review evaluated the relationship between NLR and the prognosis of patients who receive NAC.
Entinostat has been utilized in other solid tumors for its ability to induce the inhibition of cell proliferation.
Studies of asymptomatic and symptomatic patients have demonstrated lower ctDNA detection in asymptomatic patients.
In several different types of cancer, tumor budding is linked to poor survival outcomes.
The phase III study found that regorafenib improved overall survival in patients with refractory advanced gastric cancer.
Study participants were administered nadunolimab with a standard dose of gemcitabine and nab-paclitaxel (GN) every two weeks.
The SOX chemotherapy regimen for gastric cancer consists of S-1, an oral fluoropyrimidine, in combination with oxaliplatin.
Repeated use of TACE can impair liver function and stimulate tumor angiogenesis.
Dr. Richard Finn provides an overview of the key studies in liver cancer from ESMO 2024.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.